Current drug delivery最新文献

筛选
英文 中文
Engineered Exosomes for Drug Delivery in Cancer Therapy: A Promising Approach and Application. 用于癌症治疗的工程外泌体给药:前景广阔的方法和应用。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230712103942
Peiwen Fu, Siqi Yin, Huiying Cheng, Wenrong Xu, Jiajia Jiang
{"title":"Engineered Exosomes for Drug Delivery in Cancer Therapy: A Promising Approach and Application.","authors":"Peiwen Fu, Siqi Yin, Huiying Cheng, Wenrong Xu, Jiajia Jiang","doi":"10.2174/1567201820666230712103942","DOIUrl":"10.2174/1567201820666230712103942","url":null,"abstract":"<p><p>A significant amount of research effort is currently focused on investigating the role of exosomes in various cancers. These tiny vesicles, apart from acting as biomarkers, also play a crucial role in tumor formation and development. Several studies have demonstrated that exosomes can be a drug delivery vehicle for cancer therapy. In this paper, we highlight the key advantages of exosomes as a drug delivery candidate, with a particular focus on their low immunogenicity, natural targeting ability and suitable mechanical properties. Furthermore, we propose that the selection of appropriate exosomes and drug loading methods based on therapeutic goals and product heterogeneity is essential for preparing engineered exosomes. We comprehensively analyzed the superiorities of current drug-loading methods to improve the creation of designed exosomes. Moreover, we systematically review the applications of engineered exosomes in various therapies such as immunotherapy, gene therapy, protein therapy, chemotherapy, indicating that engineered exosomes have the potential to be reliable and, safe drug carriers that can address the unmet needs in cancer clinical practice.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"817-827"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10150216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Oral Bioavailability of Domperidone Maleate: Formulation, In vitro Permeability Evaluation In-caco-2 Cell Monolayers and In situ Rat Intestinal Permeability Studies. 提高马来酸多潘立酮的口服生物利用度:配方、体外渗透性评估、Caco-2 细胞单层和原位大鼠肠道渗透性研究。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230214091509
Neslihan Üstündağ Okur, Emre Şefik Çağlar, Mustafa Sinan Kaynak, Mine Diril, Saniye Özcan, Hatice Yeşim Karasulu
{"title":"Enhancing Oral Bioavailability of Domperidone Maleate: Formulation, <i>In vitro</i> Permeability Evaluation In-caco-2 Cell Monolayers and <i>In situ</i> Rat Intestinal Permeability Studies.","authors":"Neslihan Üstündağ Okur, Emre Şefik Çağlar, Mustafa Sinan Kaynak, Mine Diril, Saniye Özcan, Hatice Yeşim Karasulu","doi":"10.2174/1567201820666230214091509","DOIUrl":"10.2174/1567201820666230214091509","url":null,"abstract":"<p><strong>Background: </strong>The domperidone maleate, a lipophilic agent classified as a Biopharmaceutical Classification System Class II substance with weak water solubility. Self- Emulsifying Drug Delivery System is a novel approach to improve water solubility and, ultimately bioavailability of drugs.</p><p><strong>Objective: </strong>This study aimed to develop and characterize new domperidone-loaded self-emulsifying drug delivery systems as an alternative formulation and to evaluate the permeability of domperidone-loaded self-emulsifying drug delivery systems by using Caco-2 cells and <i>via</i> single-pass intestinal perfusion method.</p><p><strong>Methods: </strong>Three self-emulsifying drug delivery systems were prepared and characterized in terms of pH, viscosity, droplet size, zeta potential, polydispersity index, conductivity, <i>etc</i>. Each formulation underwent 10, 100, 200, and 500 times dilution in intestinal buffer pH 6.8 and stomach buffer pH 1.2, respectively. Female Sprague Dawley rats were employed for <i>in situ</i> single-pass intestinal perfusion investigations.</p><p><strong>Results: </strong>Results of the study revealed that the ideal self-emulsifying drug delivery systems formulation showed narrow droplet size, ideal zeta potential, and no conductivity. Additionally, as compared to the control groups, the optimum formulation had better apparent permeability (12.74 ± 0.02×10-4) from Caco-2 cell monolayer permeability experiments. The study also revealed greater Peff values (2.122 ± 0.892×10-4 cm/s) for the optimal formulation from <i>in situ</i> intestinal perfusion analyses in comparison to control groups (Domperidone; 0.802 ± 0.418×10-4 cm/s).</p><p><strong>Conclusion: </strong>To conclude, prepared formulations can be a promising way of oral administration of Biopharmaceutical Classification System Class II drugs.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1010-1023"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11092562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10767561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Compound Essential Oil Alters Stratum Corneum Structure, Potentially Promoting the Transdermal Permeation of Hydrophobic and Hydrophilic Ingredients. 一种复合精油能改变角质层结构,从而促进疏水性和亲水性成分的透皮渗透。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230120122206
Na Yang, Xinyi Ai, Kang Cheng, Yihan Wu, Zhi Lu, Zhenda Liu, Teng Guo, Nianping Feng
{"title":"A Compound Essential Oil Alters Stratum Corneum Structure, Potentially Promoting the Transdermal Permeation of Hydrophobic and Hydrophilic Ingredients.","authors":"Na Yang, Xinyi Ai, Kang Cheng, Yihan Wu, Zhi Lu, Zhenda Liu, Teng Guo, Nianping Feng","doi":"10.2174/1567201820666230120122206","DOIUrl":"10.2174/1567201820666230120122206","url":null,"abstract":"<p><strong>Background: </strong>The stratum corneum (SC) is the main barrier of the skin, and cosmeceuticals are different from ordinary cosmetics in that they need to deliver active ingredients targeting specific skin problems through the SC into the deeper layers of the skin. Thus, we designed a compound essential oil (CEO) extracted from <i>Salvia miltiorrhiza</i> Bge and <i>Cinnamomum cassia</i> Presl, supplemented with borneol to deliver active ingredients through the SC.</p><p><strong>Methods: </strong>The CEO was prepared by flash extraction combined with the microwave method. Moreover, the main components of the CEO were determined using gas chromatography-mass spectrometry (GCMS). Visualization techniques, such as scanning electron microscopy (SEM), haematoxylin-eosin (HE) staining, and confocal laser scanning microscopy (CLSM), were used to study the permeationpromoting mechanism of the CEO on the skin. Furthermore, the permeation-promoting effects of the CEO on both hydrophobic and hydrophilic ingredients were tested <i>via in vitro</i> skin penetration experiments and <i>in vivo</i> microdialysis experiments.</p><p><strong>Results: </strong>The results indicated the ability of the CEO to alter the structure of the SC, leading to enhanced transdermal permeation of hydrophobic and hydrophilic ingredients. The 1.5% CEO group demonstrated the best permeation-promoting effect compared to the other CEO groups and blank groups (P<0.05). Furthermore, the CEO displayed an expedited permeability-promoting effect on hydrophobic ingredients compared to hydrophilic ingredients.</p><p><strong>Conclusion: </strong>It is concluded that the prepared CEO can promote the transdermal permeation of hydrophobic and hydrophilic ingredients. This study will provide a reference for the application of the prepared CEO in the development of cosmeceuticals with natural efficacy.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"744-752"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9126742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes. 超声波介导的携带 STAT6 SiRNA 的 PLGA-PEI 纳米气泡能使肿瘤相关巨噬细胞从 M2 型恢复到 M1 型,从而增强对 NSCLC 的治疗。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230724151545
Hong Shu, Wenhao Lv, Zhi-Jian Ren, Hui Li, Tiantian Dong, Yao Zhang, Fang Nie
{"title":"Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment <i>via</i> Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes.","authors":"Hong Shu, Wenhao Lv, Zhi-Jian Ren, Hui Li, Tiantian Dong, Yao Zhang, Fang Nie","doi":"10.2174/1567201820666230724151545","DOIUrl":"10.2174/1567201820666230724151545","url":null,"abstract":"<p><strong>Background: </strong>Tumor-associated macrophages (TAMs) are crucial for non-small cell lung cancer (NSCLC) development.</p><p><strong>Objective: </strong>In this study, polylactic acid-co-glycolic acid (PLGA)-polyethylenimine (PEI) nanobubbles (NBs) carrying STAT6 siRNA were prepared and combined with ultrasound-mediated nanobubbles destruction (UMND) to silence the STAT6 gene, ultimately repolarizing TAMs from the M2 to the M1 phenotype, treating NSCLC <i>in vitro</i>.</p><p><strong>Methods: </strong>PLGA-PEI NBs-siRNA were prepared and characterised, and their respective ultrasound imaging, biological stabilities and cytotoxicities were detected. Transfection efficiency was evaluated by fluorescence microscopy and flow cytometry. Repolarization of THP-1-derived M2-like macrophages was determined by qPCR and flow cytometry. NSCLC cells (A549) were co-cultured with transfected M2-like macrophages or their associated conditioned medium (CM). Western blotting was used to detect STAT6 gene silencing in M2-like macrophages and markers of epithelial and mesenchymal in A549 cells. The proliferation of A549 cells was detected using CCK-8 and cell colony formation assays. Transwell assays were used to detect the migration and invasion of A549 cells.</p><p><strong>Results: </strong>PLGA-PEI NBs-siRNA had an average size of 223.13 ± 0.92 nm and a zeta potential of about -5.59 ± 0.97 mV. PLGA-PEI NBs showed excellent ultrasonic imaging capability in addition to biological stability to protect siRNA from degradation. UMND enhanced PLGA-PEI NBs-STAT6 siRNA transfection in M2-like macrophages, which made M2-like macrophages repolarize to M1-like macrophages and prevented proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in A549 cells.</p><p><strong>Conclusion: </strong>UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1114-1127"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10247880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer. 人工智能在癌症药物发现和靶点识别中的作用。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201821666230905090621
Vishal Sharma, Amit Singh, Sanjana Chauhan, Pramod Kumar Sharma, Shubham Chaudhary, Astha Sharma, Omji Porwal, Neeraj Kumar Fuloria
{"title":"Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer.","authors":"Vishal Sharma, Amit Singh, Sanjana Chauhan, Pramod Kumar Sharma, Shubham Chaudhary, Astha Sharma, Omji Porwal, Neeraj Kumar Fuloria","doi":"10.2174/1567201821666230905090621","DOIUrl":"10.2174/1567201821666230905090621","url":null,"abstract":"<p><p>Drug discovery and development (DDD) is a highly complex process that necessitates precise monitoring and extensive data analysis at each stage. Furthermore, the DDD process is both timeconsuming and costly. To tackle these concerns, artificial intelligence (AI) technology can be used, which facilitates rapid and precise analysis of extensive datasets within a limited timeframe. The pathophysiology of cancer disease is complicated and requires extensive research for novel drug discovery and development. The first stage in the process of drug discovery and development involves identifying targets. Cell structure and molecular functioning are complex due to the vast number of molecules that function constantly, performing various roles. Furthermore, scientists are continually discovering novel cellular mechanisms and molecules, expanding the range of potential targets. Accurately identifying the correct target is a crucial step in the preparation of a treatment strategy. Various forms of AI, such as machine learning, neural-based learning, deep learning, and network-based learning, are currently being utilised in applications, online services, and databases. These technologies facilitate the identification and validation of targets, ultimately contributing to the success of projects. This review focuses on the different types and subcategories of AI databases utilised in the field of drug discovery and target identification for cancer.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"870-886"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Landscape of Therapeutics for the Management of Hypertension - A Review. 高血压治疗药物的现状 - 综述。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230623121433
Neda Fatima, Sumel Ashique, Aakash Upadhyay, Shubneesh Kumar, Himanshu Kumar, Nitish Kumar, Prashant Kumar
{"title":"Current Landscape of Therapeutics for the Management of Hypertension - A Review.","authors":"Neda Fatima, Sumel Ashique, Aakash Upadhyay, Shubneesh Kumar, Himanshu Kumar, Nitish Kumar, Prashant Kumar","doi":"10.2174/1567201820666230623121433","DOIUrl":"10.2174/1567201820666230623121433","url":null,"abstract":"<p><p>Hypertension is a critical health problem. It is also the primary reason for coronary heart disease, stroke, and renal vascular disease. The use of herbal drugs in the management of any disease is increasing. They are considered the best immune booster to fight against several types of diseases. To date, the demand for herbal drugs has been increasing because of their excellent properties. This review highlights antihypertensive drugs, polyphenols, and synbiotics for managing hypertension. Evidence is mounting in favour of more aggressive blood pressure control with reduced adverse effects, especially for specific patient populations. This review aimed to present contemporary viewpoints and novel treatment options, including cutting-edge technological applications and emerging interventional and pharmaceutical therapies, as well as key concerns arising from several years of research and epidemiological observations related to the management of hypertension.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"662-682"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment. 作为乳腺癌治疗新疗法的单克隆抗体和抗体药物共轭物。
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230731094258
Swati Saini, Nisha Gulati, Rajendra Awasthi, Vimal Arora, Sachin Kumar Singh, Shobhit Kumar, Gaurav Gupta, Kamal Dua, Rakesh Pahwa, Harish Dureja
{"title":"Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.","authors":"Swati Saini, Nisha Gulati, Rajendra Awasthi, Vimal Arora, Sachin Kumar Singh, Shobhit Kumar, Gaurav Gupta, Kamal Dua, Rakesh Pahwa, Harish Dureja","doi":"10.2174/1567201820666230731094258","DOIUrl":"10.2174/1567201820666230731094258","url":null,"abstract":"<p><p>When breast cells divide and multiply out of control, it is called breast cancer. Symptoms include lump formation in the breast, a change in the texture or color of the breast, or a discharge from the nipple. Local or systemic therapy is frequently used to treat breast cancer. Surgical and radiation procedures limited to the affected area are examples of local management. There has been significant worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist the expansion of cancer cells by inducing the destruction of cellular membranes, blocking immune system inhibitors, and preventing the formation of new blood vessels. mAbs can also target growth factor receptors. Understanding the molecular pathways involved in tumor growth and its microenvironment is crucial for developing effective targeted cancer therapeutics. Due to their unique properties, mAbs have a wide range of clinical applications. Antibody-drug conjugates (ADCs) are drugs that improve the therapeutic index by combining an antigen-specific antibody with a payload. This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multi-specific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"993-1009"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9898276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitosan Oligosaccharide Modified Bovine Serum Albumin Nanoparticles for Improving Oral Bioavailability of Naringenin. 壳聚糖低聚糖修饰牛血清白蛋白纳米颗粒用于提高柚皮苷的口服生物利用度
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230718143726
Ruiyue Fang, Yiqi Liao, Huishuang Qiu, Yuxin Liu, Shiyuan Lin, Hui Chen
{"title":"Chitosan Oligosaccharide Modified Bovine Serum Albumin Nanoparticles for Improving Oral Bioavailability of Naringenin.","authors":"Ruiyue Fang, Yiqi Liao, Huishuang Qiu, Yuxin Liu, Shiyuan Lin, Hui Chen","doi":"10.2174/1567201820666230718143726","DOIUrl":"10.2174/1567201820666230718143726","url":null,"abstract":"<p><strong>Introduction: </strong>With the rapid development of nanotechnology, the research and development of nano-drugs have become one of the development directions of drug innovation. The encapsulation of the nanoparticles can change the biological distribution of the drug <i>in vivo</i> and improve the bioavailability of the drug <i> in vivo</i>. Naringenin is poorly soluble in water and has a low bioavailability, thus limiting its clinical application. The main purpose of this study was to develop a nano-sized preparation that could improve the oral bioavailability of naringenin.</p><p><strong>Methods: </strong>Chitosan oligosaccharide modified naringenin-loaded bovine serum albumin nanoparticles (BSA-COS@Nar NPs) were prepared by emulsification solvent evaporation and electrostatic interaction. The nanoparticles were characterized by HPLC, laser particle size analyzer, transmission electron microscope and X-ray diffraction analysis. The release <i>in vitro</i> was investigated, and the behavior of nanoparticles in rats was also studied. The caco-2 cell model was established <i>in vitro</i> to investigate the cytotoxicity and cellular uptake of nanoparticles.</p><p><strong>Results: </strong>BSA-COS@Nar NPs were successfully prepared, and the first-order release model was confirmed <i>in vitro</i> release. <i>In vivo</i> pharmacokinetic results indicated that the area under the drug concentration- time curve (AUC) of BSA-COS@Nar NPs was 2.37 times more than free naringenin. Cytotoxicity and cellular uptake results showed that BSA-COS@Nar NPs had no significant cytotoxic effect on Caco- 2 cells and promoted cellular uptake of the drug.</p><p><strong>Conclusion: </strong>BSA-COS@Nar NPs could improve the <i>in vivo</i> bioavailability of naringenin.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1142-1150"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation, Characterization and Drug Delivery Research of γ-Polyglutamic Acid Nanoparticles: A Review. γ-聚谷氨酸纳米颗粒的制备、表征和给药研究:综述
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230102140450
Zhihan Liu, Yan He, Xia Ma
{"title":"Preparation, Characterization and Drug Delivery Research of γ-Polyglutamic Acid Nanoparticles: A Review.","authors":"Zhihan Liu, Yan He, Xia Ma","doi":"10.2174/1567201820666230102140450","DOIUrl":"10.2174/1567201820666230102140450","url":null,"abstract":"<p><p>γ-Polyglutamic acid is a kind of biomaterial and environmentally friendly polymer material with the characteristics of water solubility and good biocompatibility. It has a wide range of applications in medicine, food, cosmetics and other fields. This article reviews the preparation, characterization and medical applications of γ-polyglutamic acid nanoparticles. Nanoparticles prepared by using γ- polyglutamic acid not only had the traditional advantages of enhancing drug stability and slow-release effect, but also were simple to prepare without any biological toxicity. The current methods of nanoparticle preparation mainly include the ion gel method and solvent exchange method, which use the total electrostatic force, van der Waals force, hydrophobic interaction force and hydrogen bond force between molecules to embed materials with different characteristics. At present, there are more and more studies on the use of γ-polyglutamic acid to encapsulate drugs, and the research on the mechanism of its encapsulation and sustained release has gradually matured. The development and application of polyglutamic acid nanoparticles have broad prospects.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"795-806"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10468926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local Multiple-site Injections of a Plasmid Encoding Human MnSOD Mitigate Radiation-induced Skin Injury by Inhibiting Ferroptosis. 局部多部位注射编码人类 MnSOD 的质粒可通过抑制铁凋亡减轻辐射诱发的皮肤损伤
IF 2.4 4区 医学
Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230508120720
Xiaoying Wang, Yuxin Lu, Xiaochen Cheng, Xuefeng Zhu, Dujuan Li, Haiying Duan, Shenhui Hu, Fengjun Xiao, Li Du, Qinglin Zhang
{"title":"Local Multiple-site Injections of a Plasmid Encoding Human <i>MnSOD</i> Mitigate Radiation-induced Skin Injury by Inhibiting Ferroptosis.","authors":"Xiaoying Wang, Yuxin Lu, Xiaochen Cheng, Xuefeng Zhu, Dujuan Li, Haiying Duan, Shenhui Hu, Fengjun Xiao, Li Du, Qinglin Zhang","doi":"10.2174/1567201820666230508120720","DOIUrl":"10.2174/1567201820666230508120720","url":null,"abstract":"<p><strong>Background: </strong>Most patients who undergo radiotherapy develop radiation skin injury, for which effective treatment is urgently needed. MnSOD defends against reactive oxygen species (ROS) damage and may be valuable for treating radiation-induced injury. Here, we (i) investigated the therapeutic and preventive effects of local multiple-site injections of a plasmid, encoding human MnSOD, on radiation-induced skin injury in rats and (ii) explored the mechanism underlying the protective effects of pMnSOD.</p><p><strong>Methods: </strong>The recombinant plasmid (pMnSOD) was constructed with human cytomegalovirus (CMV) promoter and pUC-ori. The protective effects of pMnSOD against 20-Gy X-ray irradiation were evaluated in human keratinocytes (HaCaT cells) by determining cell viability, ROS levels, and ferroptosisrelated gene expression. In therapeutic treatment, rats received local multiple-site injections of pMnSOD on days 12, 19, and 21 after 40-Gy γ-ray irradiation. In preventive treatment, rats received pMnSOD injections on day -3 pre-irradiation and on day 4 post-irradiation. The skin injuries were evaluated based on the injury score and pathological examination, and ferroptosis-related gene expression was determined.</p><p><strong>Results: </strong>In irradiated HaCaT cells, pMnSOD transfection resulted in an increased SOD2 expression, reduced intracellular ROS levels, and increased cell viability. Moreover, <i>GPX4</i> and <i>SLC7A11</i> expression was significantly upregulated, and erastin-induced ferroptosis was inhibited in HaCaT cells. In the therapeutic and prevention treatment experiments, pMnSOD administration produced local SOD protein expression and evidently promoted the healing of radiation-induced skin injury. In the therapeutic treatment experiments, the injury score in the high-dose pMnSOD group was significantly lower than in the PBS group on day 33 post-irradiation (1.50<i> vs</i>. 2.80, <i>P</i> < 0.05). In the prevention treatment experiments, the skin injury scores were much lower in the pMnSOD administration groups than in the PBS group from day 21 to day 34. <i>GPX4, SLC7A11</i>, and <i>Bcl-2</i> were upregulated in irradiated skin tissues after pMnSOD treatment, while <i>ACSL4</i> was downregulated.</p><p><strong>Conclusion: </strong>The present study provides evidence that the protective effects of MnSOD in irradiated HaCaT cells may be related to the inhibition of ferroptosis. The multi-site injections of pMnSOD had clear therapeutic and preventive effects on radiation-induced skin injury in rats. pMnSOD may have therapeutic value for the treatment of radiation-induced skin injury.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"763-774"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9425128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信